The potential impact of the 2020 US presidential election on global health care pricing

The expert teams of MArS and PSE will summarize the results of the US presidential election before detailed discussions and finding on the potential health care changes and its global impact will be discussed. Most likely the potential price referencing of US prices to a global country basket will be included as other specific items.

Register now for the free webinar on November 24 2020at 9pm CET / noon PT: Register

Innovative price contracting in the German AMNOG process – is this the future or just a dream?

The presenters Dr. Stefan Walzer and Roman Spelsberg analyzed the current situation of the AMNOG process with respect to price contracting. They will show opportunities and hurdles of the current system as well as current examples. Furthermore, they will also come up with a suggestion how innovative contracting could be implemented in Germany – even further…

 

Register now for our new free webinar! https://us02web.zoom.us/webinar/register/3016007018391/WN_jAWzjHTbSK2m2fUXJoqLtg

Market Access & reimbursement for digital health applications

In Germany, a new market access and reimbursement process for digital health applications (DiGAs) was introduced in early 2020. In our approx. 45-minute webinar, you will learn what this new process looks like and which similar processes may exist in a European comparison. The French expert Guy Eiferman from the Market Access consulting agency Nextep will speak about the French process. The webinar will conclude with a panel discussion on the main differences and similarities between France and Germany as driving forces for digital innovation in Europe.

Register now!!

Start-up failures – How can you plan for a successful market launch?

In a recent study funded by the Dutch government it was found that roughly 91% of start-ups fail! What are the reasons for that and more important how could you plan to be successful? MArS in cooperation with the Dutch consultancy Seijgraaf will present and discuss findings and solutions for a successful market access of health care start-ups. The webinar will include the following topics: • What are the major issues health care start-ups have when preparing to enter the launch? • What are must-haves in terms of market access and reimbursement for new products in the health care system? • How can a health care start-up be successful?

New Webinar on Covid-19 and digitalization on May 28 2020

The covid-19 outbreak has had a significant impact on daily life of populations and health care systems. Due to physical distancing as a core policy, digitalization is a main opportunity also in health care. At the same time the new law for digitalization in health care (DiGA) was made effective In Germany.

The MArS Covid-19 task force will show you in this webinar:

  • How digitalization has changed the health care system
  • The different pathways for digitalization solutions to the German market

Register now: Webinars

Covid-19 crisis makes KOLs availability difficult – MArS has the solution

Given the covid-19 crisis, most clinical KOLs are no more able to attend any physical meetings or even phone calls due to the heavy work load in some areas of the D-A-CH countries!
MArS is working since years in a step-wise approach for such situations, when KOLs might be difficult to be approached:
  • Physical Advisory Board Meeting
  • Virtual Advisory Board Meeting
  • Virtual Delphi Panel

Please contact us directly and get your tailor-made solution to stay in contact with your KOLs: stefan.walzer@marketaccess-pricingstrategy.de

Work environment given the COVID-19 outbreak

Dear clients, network partners, friends!!

Most of companies are moving now into home-office-based business given the outbreak of the COVID-19 virus! Home-office sounds easy, it is not always, especially if you have not (yet) a grown culture on that kind of work.

We at MArS always work from our home-offices, and we have specific tricks and recommendations you need to follow in order to make it successful! On the work environment section of our website you can find already some suggestions.

But please take this as an offer: Contact me or any MArS member to get insights how home-office can be made a successful story given the difficult situation we are currently all in.

Take care and stay at home!!

New analysis on external reference pricing shows negative impact on drug availability

Kanavos et al. just published another analysis on external reference pricing (ERP). ERP is widely applied by many payers across the world and also delivers short term cost savings for health care systems. Conclusions by Kanavos et al. are as follows: “ERP has not regulated prices efficiently and has unintended consequences that reduce the benefits arising from it. If ERP is carefully designed with minimal price revisions, prudent selection of basket size and countries, and consideration of transaction prices, it could be a more effective mechanism enhancing welfare, equitable access to medicines within countries and help promote industry innovation.”

The full article is available in the European Journal of Health Economics.

MArS has experience in pricing research and strategy as well as in price negotiations and can hence assess the ERP impact on the D-A-CH countries in detail.

MArS teaching at the MedTech Startup School in Tuebingen / Germany

At the start of a product’s lifecycle there are many questions to be answered and many processes to be planned. One of the core areas to cover is pricing and reimbursement as this has a direct impact on the price and patient outreach (“availability”) and hence a company’s revenues flow. MArS is teaching the tools and processes as tutors at the Startup School Tuebingen with a variety of new companies and various bright business ideas.

With our experience in pricing planning, insurance contacts, submissions and negotiations we can help driving a company through the endeavor of market access from the early days until the end.

Price negotiation article published – link MArS negotiation boot camp

Price negotiation strategy is most of the times also linked to the available evidence and the potential bet on future data. Gladwell et al. have just published a nice simulation approach with the example in the UK which can also be utilized in the D-A-CH context. For the German AMNOG that approach is also relevant for orphan drugs earlier in the process also with the G-BA and for any pharmaceutical within the price negotiations with the GKV-SV.

The article is available in Value in Health.

MArS has long-lasting experience in (price) negotiations in the D-A-CH regions. We have also developed an internal and successful negotiation boot camp utilizing virtual reality. Contact us for a live demonstration.